Premji Invest

Premji Invest, the Bengaluru-based family office of Wipro founder Azim Premji, is one of the largest and most disciplined pools of growth capital in India and a structurally important investor across healthcare delivery, diagnostics, and increasingly AI-enabled health platforms. The firm is best known in healthcare for its long-standing partnership with Manipal Hospitals and follow-on positions in companies like MedPlus, NewEra Hospitals, and TI Medical, which signals a pattern of preferring asset-heavy delivery and consumables over pure software bets. Cheques typically start in the $25M-plus range at Series B, Series C, and growth, and the fund is happy to anchor secondaries and pre-IPO rounds. Founders building tech-enabled hospital networks, diagnostic chains, and clinically validated AI/ML platforms with credible revenue should approach; pre-revenue healthcare-AI experiments and Seed-stage digital health plays should look elsewhere. The right entry path is through a Premji portfolio CEO, a respected sell-side banker (Avendus, Kotak, JP Morgan India), or a senior Wipro alumnus who can carry the introduction. In your pitch, lead with audited unit economics, multi-year EBITDA trajectory, governance maturity, and a credible IPO or strategic exit path; soft narrative will not survive their diligence cadence. Caveats: Premji moves slowly relative to growth-stage international funds, prefers majority or significant minority positions, and is more comfortable with traditional healthcare delivery economics than with frontier generative AI risk profiles. Their conviction on AI/ML in healthcare is real but selective, so come with evidence of clinical adoption, regulatory clearance, and durable distribution rather than model novelty. Founders raising under $50M and not yet at scale will likely find the conversation educational but premature; come back when revenue and predictability justify the cheque.